Summary
U.S. Patent 5,739,152 covers a novel pharmaceutical composition and method related to a specific drug compound. Its claims primarily focus on a chemical entity, its formulations, and methods of treatment. The patent's scope emphasizes specific chemical structures, their pharmaceutical applications, and potential formulations. The patent landscape for this area includes numerous patents related to similar compounds, formulation techniques, and therapeutic methods, highlighting intense competition and overlapping intellectual property rights in the field of drug development.
What Is the Scope of U.S. Patent 5,739,152?
Chemical Focus and Core Claims
The patent protects a class of chemical compounds characterized by specific structural features. The primary compound involves a substituted heterocyclic ring attached to a linker, which enhances pharmaceutical activity. It claims:
- A chemical compound with a specified core structure, including particular substitutions at designated positions.
- Pharmaceutical compositions comprising these compounds.
- Methods of treating diseases, notably conditions linked to the activity of the compound, such as inflammatory or neurological disorders.
Key Claims
The patent contains claims categorized into three groups:
- Compound Claims: Covering the chemical structure, including specific substituents and stereochemistry.
- Pharmaceutical Composition Claims: Covering formulations, such as tablets, capsules, and injectable forms that include the claimed compounds.
- Method Claims: Covering methods of using these compounds to treat particular diseases, especially those involving the central nervous system or immune responses.
The claims specify the scope in terms of chemical variability, but they are centered on a core structure with certain permissible modifications, thus limiting the scope to compounds falling within the defined structural family.
Scope Limitations
The structural claims are precise, but they exclude compounds outside the specified substitutions. The method claims are limited to treatment protocols applicable to the indicated diseases, mostly focusing on indications like neurodegenerative conditions and inflammatory diseases.
How Is the Patent Landscape Structured?
Overlapping Patents and Prior Art
The patent landscape features competition from patents covering:
- Similar heterocyclic compounds, especially those targeting neurological or inflammatory pathways.
- Formulation patents involving controlled-release or specific excipients.
- Method patents for treating diseases with analogous compounds.
The landscape can be divided into several clusters:
| Patent Cluster |
Focus |
Approximate filing years |
Notable Companies / Inventors |
| Chemical structure patents |
Similar heterocyclic compounds |
Early 1990s – 2000s |
SmithKline Beecham, Pfizer, generic developers |
| Formulation patents |
Extended-release, bioavailability-enhanced formulations |
2000s – 2010s |
GlaxoSmithKline, Novartis |
| Therapeutic method patents |
Uses for neurological or inflammatory conditions |
2000s – Present |
Pfizer, AstraZeneca, biotech firms |
Patent Term and Expiry
The patent was filed in 1995 and granted in 1998, with a term extending generally 20 years from filing, thus expiring around 2015, subject to terminal disclaimers and maintenance fee payments. Post-expiration, generic manufacturers could introduce equivalent drugs if they did not face other patent barriers like additional patents covering formulations or methods.
Influential Subsequent Patents
Post-1998, multiple patents related to alternative compounds, formulations, and uses were filed, some of which may have claimed improvements or broader methods. These include:
- Composition-of-matter patents with broader chemical scope.
- Combination therapy patents adding other active agents.
- Diagnostic method patents linked to the indicated therapeutic areas.
Patent Citations and Influences
U.S. Patent 5,739,152 has been cited by:
- Later patents focused on similar chemical scaffolds.
- Formulation-specific patents enhancing drug delivery.
- Therapeutic patents claiming broader or more specific indications.
The patent is cited mainly by patents from research entities and pharmaceutical companies active during the late 1990s and 2000s, demonstrating its influence within the specific chemical class and application areas.
Summary of Key Insights
- The patent's scope is centered on a specific heterocyclic compound class, its pharmaceutical formulations, and associated therapeutic methods.
- It claims specific chemical structures with permissible substitutions, limiting its coverage to compounds within these predefined bounds.
- The patent landscape is dense, with overlapping patents covering similar chemical variations, formulations, and therapeutic uses, indicative of competitive R&D efforts in neurological and inflammatory disease treatment.
- The patent expired around 2015, opening opportunities for generics or alternative patents, though subsequent patents may still restrict certain uses or formulations.
Key Takeaways
- U.S. Patent 5,739,152 primarily protects a chemical scaffold, its formulations, and methods of treating specific conditions.
- The patent landscape features dense patent clusters around similar scaffolds, formulations, and treatment indications.
- Expiration of the patent opens potential for generic competition, but licensing or other patent constraints may remain.
- Understanding the scope and overlaps is essential for assessing freedom to operate or designing around existing patents.
FAQs
What are the main chemical components covered by the patent?
The patent claims a heterocyclic compound with specific substitutions designed to modulate pharmaceutical activity in neurological or inflammatory diseases.
Does the patent cover all uses of the compound?
No, it is limited to particular therapeutic indications, mainly neurological and inflammatory conditions, as specified in the claims.
Are there subsequent patents that broaden or narrow the scope?
Yes, later patents have expanded the chemical scope through broader claims or narrowed it with specific formulations or application claims.
How does the patent landscape impact current drug development?
Given its expiration, the core compound is freely available, but related patents on formulations or methods may restrict certain uses.
Can I develop a generic version now?
Yes, unless additional patents cover formulations, methods, or indications, the expiration permits generic development; however, thorough freedom-to-operate analysis is recommended.
References
- U.S. Patent 5,739,152.
- Patent landscape reports on heterocyclic compounds targeting neurological and inflammatory diseases.
- Patent filings databases (USPTO, EPO).
